Neos Therapeutics, Inc. (NEOS) Analysts See $-0.22 EPS

Neos Therapeutics, Inc. (NASDAQ:NEOS) Logo

Analysts expect Neos Therapeutics, Inc. (NASDAQ:NEOS) to report $-0.22 EPS on May, 9 before the open.They anticipate $0.28 EPS change or 56.00 % from last quarter’s $-0.5 EPS. After having $-0.23 EPS previously, Neos Therapeutics, Inc.’s analysts see -4.35 % EPS growth. The stock decreased 6.22% or $0.14 during the last trading session, reaching $2.11. About 178,633 shares traded. Neos Therapeutics, Inc. (NASDAQ:NEOS) has declined 73.25% since May 8, 2018 and is downtrending. It has underperformed by 77.62% the S&P500.

Neos Therapeutics, Inc. (NASDAQ:NEOS) Ratings Coverage

Among 2 analysts covering Neos Therapeutics (NASDAQ:NEOS), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neos Therapeutics had 4 analyst reports since November 12, 2018 according to SRatingsIntel. The stock of Neos Therapeutics, Inc. (NASDAQ:NEOS) has “Buy” rating given on Thursday, March 14 by Cantor Fitzgerald. As per Monday, November 12, the company rating was maintained by JMP Securities.

Neos Therapeutics, Inc., a pharmaceutical company, engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies. The company has market cap of $104.91 million. The Company’s product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. It currently has negative earnings. The firm makes and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older.

More notable recent Neos Therapeutics, Inc. (NASDAQ:NEOS) news were published by: Globenewswire.com which released: “Neos Therapeutics Licenses Pipeline Candidate for Treatment of Sialorrhea (Excessive Drooling) – GlobeNewswire” on October 23, 2018, also Seekingalpha.com with their article: “PDL BioPharma: Get In Before Buybacks Begin, Thanks To SevenSaoi Capital – Seeking Alpha” published on October 04, 2018, Nasdaq.com published: “Crypto Exchange Poloniex Dumps Eight Underperforming Coins – Nasdaq” on September 19, 2018. More interesting news about Neos Therapeutics, Inc. (NASDAQ:NEOS) were released by: Livetradingnews.com and their article: “Neos Therapeutics, Inc. (NASDAQ:NEOS) Value Stock at $6.50 – Live Trading News” published on June 11, 2018 as well as Streetinsider.com‘s news article titled: “Form DEF 14A Lifeway Foods, Inc. For: Jun 20 – StreetInsider.com” with publication date: April 30, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.